Can I Take Berberine with Rezdiffra (Resmetirom)?

What resmetirom is, and why its metabolism matters here

Resmetirom is a selective thyroid hormone receptor-beta (THR-beta) agonist, approved by the FDA in March 2024 under the brand name Rezdiffra for adults with metabolic dysfunction-associated steatohepatitis (MASH) and moderate to advanced liver fibrosis (stages F2-F3), used alongside diet and exercise. It is the first drug approved specifically for this indication.

Resmetirom is cleared mainly through the liver enzyme CYP3A4, with a smaller contribution from CYP2C8, and it is also a substrate of the P-glycoprotein (P-gp) transporter. The FDA prescribing information advises avoiding strong CYP3A4 inhibitors and using caution with moderate CYP3A4 inhibitors, because raising resmetirom's blood level shifts it outside the exposure range studied in its approval trials (source: FDA label, accessdata.fda.gov, current as of the 2024 label; verify against the current label for any update).

What berberine is, and why MASH patients are likely to be taking it

Berberine is a plant-derived alkaloid found in barberry, goldenseal, and Oregon grape, sold over the counter as a metabolic-support supplement and often marketed informally as "nature's metformin." It is widely used by people with insulin resistance, prediabetes, or fatty liver disease, which means a meaningful share of patients starting resmetirom will already be taking it, or will ask about starting it. That overlap is what makes this an urgent practical question rather than an abstract pharmacology exercise, even though it has not been studied directly.

Berberine's proposed mechanism is activation of AMP-activated protein kinase (AMPK), the same energy-sensing pathway targeted by metformin, and small trials have reported reductions in fasting glucose and triglycerides with regular use. Separately, berberine has been studied in non-alcoholic fatty liver disease for effects on liver fat and ALT. The exact magnitude of these effects varies across the published literature, and the specific trial identifiers commonly cited for these numbers should be verified against the primary literature before being restated as fact in a clinical setting.

The core interaction concern

Berberine has been reported in pharmacokinetic studies to inhibit CYP3A4 and P-glycoprotein at commonly used supplemental doses, based on its effect on the blood levels of other CYP3A4-metabolized drugs. Resmetirom depends on both of those pathways for elimination. If berberine meaningfully inhibits either pathway, resmetirom blood levels could rise above the range studied in its approval trials, which is the basis for the FDA label's general caution about CYP3A4 inhibitors. This is a mechanistic, first-principles concern rather than a finding from a study of the two agents together, and it has not been confirmed or excluded by any dedicated trial as of mid-2025.

A second, independent concern is pharmacodynamic overlap. Resmetirom lowers LDL cholesterol and triglycerides as part of its intended effect, and improves hepatic insulin sensitivity secondarily. Berberine lowers glucose and triglycerides through its own AMPK-driven mechanism. Adding the two together is more likely to produce additive lowering of lipids and glucose than a dangerous interaction on its own, but for a patient already on metformin, an SGLT-2 inhibitor, or a GLP-1 receptor agonist, an additional glucose-lowering supplement changes the overall glucose-lowering load in a way worth discussing with the prescriber.

Both compounds also touch liver enzyme levels, in opposite directions in some reports: berberine has been associated with ALT reduction in fatty liver disease studies, while resmetirom causes dose-related transaminase elevation in a minority of patients in its approval trials. The net effect of combining them on ALT and AST is not predictable from either mechanism alone, which is exactly why monitoring, not prediction, is the practical answer.

What is established, what is plausible, and what is not established

Established: Resmetirom is metabolized primarily through CYP3A4, with P-gp as a secondary transport pathway, and its FDA label instructs caution or avoidance with CYP3A4 inhibitors of moderate or strong potency. Berberine has documented effects on glucose and triglycerides in trials of berberine alone, and has been reported to inhibit CYP3A4 and P-gp in pharmacokinetic studies of other CYP3A4 substrates.

Plausible but unproven: That berberine, taken concurrently with resmetirom, raises resmetirom blood levels enough to meaningfully increase its adverse-effect rate (nausea, diarrhea, transaminase elevation) or alter its efficacy. That the additive glucose and lipid effects of the combination provide extra clinical benefit beyond resmetirom alone.

Not established: Any specific rate of interaction, any confirmed change in resmetirom exposure when berberine is co-administered, and any confirmed benefit or harm from combining the two in real patients. No published trial, case series, or pharmacokinetic study of berberine plus resmetirom together was identified as of July 2025. This absence of direct data is itself the central fact of this page, and it should not be papered over with numbers borrowed from studies of each agent separately.

Evidence-status interaction assessment: berberine + resmetirom

A reasonable monitoring approach if a clinician approves concurrent use

There is no established, trial-verified protocol for this specific combination. The following is a conservative, first-principles approach drawn from the FDA label's general CYP3A4 caution and standard hepatology monitoring practice, not from a study of berberine and resmetirom together.

• Disclose berberine dose and formulation to the prescribing clinician before starting resmetirom, or before adding berberine to an existing resmetirom regimen.
• Obtain baseline ALT, AST, total bilirubin, fasting glucose (and HbA1c if diabetic), and a fasting lipid panel.
• If concurrent use is approved, consider a lower berberine dose (for example 500 mg once or twice daily) rather than higher supplement-range doses, to limit the degree of CYP3A4/P-gp inhibition.
• Recheck ALT and AST around 4 weeks after starting the combination, along with a symptom check for nausea, diarrhea, or right upper quadrant discomfort, since these are known resmetirom adverse effects that could intensify with higher drug exposure.
• Repeat a full liver panel and fasting lipid panel around 12 weeks.
• Stop berberine and contact the prescribing clinician promptly if ALT or AST rises above three times the upper limit of normal, or if jaundice, dark urine, or right upper quadrant pain develops.

Patients on statins metabolized by CYP3A4 (such as simvastatin, lovastatin, or atorvastatin) and also taking berberine add a third variable to this picture, since berberine's CYP3A4 inhibition could affect statin levels at the same time. That combination warrants its own conversation with a pharmacist or prescriber, including creatine kinase monitoring if muscle symptoms appear.

What professional guidance says about supplements in MASH generally

The American Association for the Study of Liver Diseases (AASLD) publishes practice guidance on MASH management and has emphasized reviewing all dietary supplement and over-the-counter product use in patients with liver disease, given the potential for hepatotoxicity and drug interactions with newer MASH therapies. Readers should consult the current AASLD guidance directly rather than rely on a paraphrase, since guidance documents are updated over time.

Alternatives some patients discuss with their clinician

Patients looking for a metabolic-support supplement with a different interaction profile sometimes ask about prescription icosapentaenoic acid (a purified omega-3 fatty acid), vitamin E, or coenzyme Q10. These have different mechanisms than berberine and are not established substitutes for it, and none has been studied in combination with resmetirom either. Any switch should be discussed with the prescribing clinician, not made independently, since the comparative evidence for MASH-specific benefit varies across these options.

Special populations

Type 2 diabetes. A large share of MASH patients also have type 2 diabetes. Adding berberine on top of resmetirom and existing antidiabetic medication increases the number of glucose-lowering agents in the regimen and warrants closer glucose monitoring, including periodic HbA1c.

Cirrhosis. Resmetirom's approval covers fibrosis stages F2-F3; patients with compensated cirrhosis were not the population studied in its pivotal trial. Both resmetirom and berberine are hepatically metabolized, so impaired liver function could raise exposure to either compound unpredictably. Berberine is not well studied in patients with cirrhosis, which argues for extra caution and direct hepatology input rather than self-management.

Statin users. See the monitoring section above regarding the added CYP3A4 variable.

When to seek urgent care

New jaundice, dark urine, pale stools, right upper quadrant pain, confusion, or unusual bruising or bleeding after starting or changing either resmetirom or berberine warrants prompt medical evaluation rather than waiting for a scheduled follow-up lab draw.